Abstract
Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.
| Original language | English |
|---|---|
| Pages (from-to) | 784-789 |
| Number of pages | 6 |
| Journal | Journal of Cardiovascular Pharmacology |
| Volume | 30 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1997 |
Fingerprint
Keywords
- Carotid intimal-medial thickness
- HDL cholesterol
- Hypercholesterolemia
- LDL cholesterol
- Probucol
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology
Cite this
Clinical evaluation of probucol in hypercholesterolemia : Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. / Baldassarre, Damiano; Franceschini, Guido; Peruzzotti, Giulia; Brusoni, Bruno; Sirtori, Cesare R.
In: Journal of Cardiovascular Pharmacology, Vol. 30, No. 6, 12.1997, p. 784-789.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical evaluation of probucol in hypercholesterolemia
T2 - Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression
AU - Baldassarre, Damiano
AU - Franceschini, Guido
AU - Peruzzotti, Giulia
AU - Brusoni, Bruno
AU - Sirtori, Cesare R.
PY - 1997/12
Y1 - 1997/12
N2 - Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.
AB - Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics. Probucol was administered as a single drug at the standard dose (0.5 g tables b.i.d.) for at least 6 months. One-hundred (71%) patients displayed a reduction of low-density lipoprotein cholesterol (LDL-C), which was significantly correlated with the baseline LDL-C level (r = 0.64; p <0.0001). Most of the patients (90%) also responded with a reduction of high- density lipoprotein cholesterol (HDL-C); the HDL-C reduction was also directly related to baseline HDL cholesterolemia (r = 0.67, p <0.0001). A highly significant correlation was found between the individual LDL-C and HDL-C responses. Eleven patients who continued with probucol treatment had a B-mode ultrasonographic investigation performed at baseline and after 24 months. No changes in carotid mean and maximal intimal-medial thickness were recorded, in contrast to an increase (i.e., indicative of atherosclerosis progression) in matched patients with hypercholesterolemia receiving other lipid-lowering regimens. Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL- C levels.
KW - Carotid intimal-medial thickness
KW - HDL cholesterol
KW - Hypercholesterolemia
KW - LDL cholesterol
KW - Probucol
UR - http://www.scopus.com/inward/record.url?scp=0031425143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031425143&partnerID=8YFLogxK
U2 - 10.1097/00005344-199712000-00013
DO - 10.1097/00005344-199712000-00013
M3 - Article
C2 - 9436818
AN - SCOPUS:0031425143
VL - 30
SP - 784
EP - 789
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
SN - 0160-2446
IS - 6
ER -